<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">36810359</PMID><DateCompleted><Year>2023</Year><Month>02</Month><Day>24</Day></DateCompleted><DateRevised><Year>2023</Year><Month>04</Month><Day>10</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2045-2322</ISSN><JournalIssue CitedMedium="Internet"><Volume>13</Volume><Issue>1</Issue><PubDate><Year>2023</Year><Month>Feb</Month><Day>21</Day></PubDate></JournalIssue><Title>Scientific reports</Title><ISOAbbreviation>Sci Rep</ISOAbbreviation></Journal><ArticleTitle>Risk of systemic lupus erythematosus flares according to autoantibody positivity at the time of diagnosis.</ArticleTitle><Pagination><StartPage>3068</StartPage><MedlinePgn>3068</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">3068</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1038/s41598-023-29772-w</ELocationID><Abstract><AbstractText>To estimate the risk of systemic lupus erythematosus (SLE) flares based on the autoantibody positivity at the time of SLE diagnosis. This retrospective cohort study included 228 patients with newly diagnosed SLE. Clinical characteristics including autoantibody positivity at the time of diagnosis of SLE were reviewed. Flares were defined as a new British Isles Lupus Assessment Group (BILAG) A score or BILAG B score for at least one organ system. Multivariable Cox regression analyses were performed to estimate the risk of flares according to autoantibody positivity. Anti-dsDNA, anti-Sm, anti-U1RNP, anti-Ro, and anti-La antibodies (Abs) were positive in 50.0%, 30.7%, 42.5%, 54.8%, and 22.4% of the patients, respectively. The incidence rate of flares was 28.2/100 person-years. Multivariable Cox regression analysis, adjusted for potential confounders, revealed that anti-dsDNA Ab positivity (adjusted hazard ratio [HR]: 1.46, p&#x2009;=&#x2009;0.037) and anti-Sm Ab positivity (adjusted HR: 1.81, p&#x2009;=&#x2009;0.004) at the time of diagnosis of SLE were associated with higher risk of flares. To better delineate the flare risk, patients were categorized as double-negative, single-positive, double-positive for anti-dsDNA and anti-Sm Abs. Compared with double-negativity, double-positivity (adjusted HR: 3.34, p&#x2009;&lt;&#x2009;0.001) was associated with higher risk of flares, while anti-dsDNA Ab single-positivity (adjusted HR: 1.11, p&#x2009;=&#x2009;0.620) or anti-Sm Ab single-positivity (adjusted HR: 1.32, p&#x2009;=&#x2009;0.270) was not associated with higher risk of flares. Patients who are double-positive for anti-dsDNA and anti-Sm Abs at the time of the diagnosis of SLE are at higher risk of flares and may benefit from stringent monitoring and early preventive treatment.</AbstractText><CopyrightInformation>&#xa9; 2023. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Kwon</LastName><ForeName>Oh Chan</ForeName><Initials>OC</Initials><AffiliationInfo><Affiliation>Division of Rheumatology, Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Park</LastName><ForeName>Min-Chan</ForeName><Initials>MC</Initials><AffiliationInfo><Affiliation>Division of Rheumatology, Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea. mcpark@yuhs.ac.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Gangnam Severance Hospital, Yonsei University College of Medicine, 211 Eonjuro, Gangnam-Gu, Seoul, 06273, Korea. mcpark@yuhs.ac.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>02</Month><Day>21</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Sci Rep</MedlineTA><NlmUniqueID>101563288</NlmUniqueID><ISSNLinking>2045-2322</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D001323">Autoantibodies</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000974">Antibodies, Antinuclear</NameOfSubstance></Chemical><Chemical><RegistryNumber>9007-49-2</RegistryNumber><NameOfSubstance UI="D004247">DNA</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001323" MajorTopicYN="Y">Autoantibodies</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008180" MajorTopicYN="Y">Lupus Erythematosus, Systemic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000974" MajorTopicYN="N">Antibodies, Antinuclear</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004247" MajorTopicYN="N">DNA</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement>The authors declare no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>5</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>2</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>2</Month><Day>22</Day><Hour>14</Hour><Minute>35</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>2</Month><Day>23</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>2</Month><Day>25</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36810359</ArticleId><ArticleId IdType="pmc">PMC9945423</ArticleId><ArticleId IdType="doi">10.1038/s41598-023-29772-w</ArticleId><ArticleId IdType="pii">10.1038/s41598-023-29772-w</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Tsang ASMWP, Bultink IEM. New developments in systemic lupus erythematosus. Rheumatol. Oxf. 2021;60:vi21&#x2013;vi28. doi: 10.1093/rheumatology/keab498.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/rheumatology/keab498</ArticleId><ArticleId IdType="pmc">PMC8709564</ArticleId><ArticleId IdType="pubmed">34951924</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsokos GC. Systemic lupus erythematosus. N. Engl. J. Med. 2011;365:2110&#x2013;2121. doi: 10.1056/NEJMra1100359.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMra1100359</ArticleId><ArticleId IdType="pubmed">22129255</ArticleId></ArticleIdList></Reference><Reference><Citation>Arbuckle MR, et al. Development of autoantibodies before the clinical onset of systemic lupus erythematosus. N. Engl. J. Med. 2003;349:1526&#x2013;1533. doi: 10.1056/NEJMoa021933.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa021933</ArticleId><ArticleId IdType="pubmed">14561795</ArticleId></ArticleIdList></Reference><Reference><Citation>Raissi TC, Hewson C, Pope JE. Repeat testing of antibodies and complements in systemic lupus erythematosus: When is it enough? J. Rheumatol. 2018;45:827&#x2013;834. doi: 10.3899/jrheum.161365.</Citation><ArticleIdList><ArticleId IdType="doi">10.3899/jrheum.161365</ArticleId><ArticleId IdType="pubmed">29657153</ArticleId></ArticleIdList></Reference><Reference><Citation>Lam GK, Petri M. Assessment of systemic lupus erythematosus. Clin. Exp. Rheumatol. 2005;23:S120&#x2013;132.</Citation><ArticleIdList><ArticleId IdType="pubmed">16273796</ArticleId></ArticleIdList></Reference><Reference><Citation>Isenberg DA, Manson JJ, Ehrenstein MR, Rahman A. Fifty years of anti-ds DNA antibodies: Are we approaching journey&#x2019;s end? Rheumatol. Oxf. 2007;46:1052&#x2013;1056. doi: 10.1093/rheumatology/kem112.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/rheumatology/kem112</ArticleId><ArticleId IdType="pubmed">17500073</ArticleId></ArticleIdList></Reference><Reference><Citation>Pisetsky DS. Anti-DNA antibodies&#x2013;quintessential biomarkers of SLE. Nat. Rev. Rheumatol. 2016;12:102&#x2013;110. doi: 10.1038/nrrheum.2015.151.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrrheum.2015.151</ArticleId><ArticleId IdType="pubmed">26581343</ArticleId></ArticleIdList></Reference><Reference><Citation>Alba P, et al. Anti-dsDNA, anti-Sm antibodies, and the lupus anticoagulant: significant factors associated with lupus nephritis. Ann. Rheum. Dis. 2003;62:556&#x2013;560. doi: 10.1136/ard.62.6.556.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/ard.62.6.556</ArticleId><ArticleId IdType="pmc">PMC1754557</ArticleId><ArticleId IdType="pubmed">12759294</ArticleId></ArticleIdList></Reference><Reference><Citation>Arroyo-&#xc1;vila M, et al. Clinical associations of anti-Smith antibodies in PROFILE: A multi-ethnic lupus cohort. Clin. Rheumatol. 2015;34:1217&#x2013;1223. doi: 10.1007/s10067-015-2941-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10067-015-2941-y</ArticleId><ArticleId IdType="pmc">PMC4475431</ArticleId><ArticleId IdType="pubmed">25896533</ArticleId></ArticleIdList></Reference><Reference><Citation>Lian F, et al. Clinical features and independent predictors of pulmonary arterial hypertension in systemic lupus erythematosus. Rheumatol. Int. 2012;32:1727&#x2013;1731. doi: 10.1007/s00296-011-1880-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00296-011-1880-4</ArticleId><ArticleId IdType="pubmed">21437686</ArticleId></ArticleIdList></Reference><Reference><Citation>Pisetsky DS. Antinuclear antibody testing&#x2014;Misunderstood or misbegotten? Nat. Rev. Rheumatol. 2017;13:495&#x2013;502. doi: 10.1038/nrrheum.2017.74.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrrheum.2017.74</ArticleId><ArticleId IdType="pubmed">28541299</ArticleId></ArticleIdList></Reference><Reference><Citation>Hoffman IE, et al. Specific antinuclear antibodies are associated with clinical features in systemic lupus erythematosus. Ann. Rheum. Dis. 2004;63:1155&#x2013;1158. doi: 10.1136/ard.2003.013417.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/ard.2003.013417</ArticleId><ArticleId IdType="pmc">PMC1755119</ArticleId><ArticleId IdType="pubmed">15308527</ArticleId></ArticleIdList></Reference><Reference><Citation>Pons-Estel GJ, Alarc&#xf3;n GS, Scofield L, Reinlib L, Cooper GS. Understanding the epidemiology and progression of systemic lupus erythematosus. Semin. Arthritis Rheum. 2010;39:257&#x2013;268. doi: 10.1016/j.semarthrit.2008.10.007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.semarthrit.2008.10.007</ArticleId><ArticleId IdType="pmc">PMC2813992</ArticleId><ArticleId IdType="pubmed">19136143</ArticleId></ArticleIdList></Reference><Reference><Citation>Ruperto N, et al. International consensus for a definition of disease flare in lupus. Lupus. 2011;20:453&#x2013;462. doi: 10.1177/0961203310388445.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/0961203310388445</ArticleId><ArticleId IdType="pubmed">21148601</ArticleId></ArticleIdList></Reference><Reference><Citation>Langham J, et al. Disease severity, flares and treatment patterns in adults with systemic lupus erythematosus in the UK: A real-world observational retrospective cohort analysis. Rheumatol. Adv. Pract. 2021;5:rkab061. doi: 10.1093/rap/rkab061.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/rap/rkab061</ArticleId><ArticleId IdType="pmc">PMC8452998</ArticleId><ArticleId IdType="pubmed">34557623</ArticleId></ArticleIdList></Reference><Reference><Citation>Ugarte-Gil MF, et al. The number of flares patients experience impacts on damage accrual in systemic lupus erythematosus: Data from a multiethnic Latin American cohort. Ann. Rheum. Dis. 2015;74:1019&#x2013;1023. doi: 10.1136/annrheumdis-2013-204620.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/annrheumdis-2013-204620</ArticleId><ArticleId IdType="pubmed">24525909</ArticleId></ArticleIdList></Reference><Reference><Citation>Pan N, et al. A surge in anti-dsDNA titer predicts a severe lupus flare within 6 months. Lupus. 2014;23:293&#x2013;298. doi: 10.1177/0961203313515763.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/0961203313515763</ArticleId><ArticleId IdType="pubmed">24316605</ArticleId></ArticleIdList></Reference><Reference><Citation>Linnik MD, et al. Relationship between anti-double-stranded DNA antibodies and exacerbation of renal disease in patients with systemic lupus erythematosus. Arthritis Rheum. 2005;52:1129&#x2013;1137. doi: 10.1002/art.20980.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.20980</ArticleId><ArticleId IdType="pubmed">15818711</ArticleId></ArticleIdList></Reference><Reference><Citation>ter Borg EJ, Horst G, Hummel EJ, Limburg PC, Kallenberg CG. Measurement of increases in anti-double-stranded DNA antibody levels as a predictor of disease exacerbation in systemic lupus erythematosus. A long-term, prospective study. Arthritis Rheum. 1990;33:634&#x2013;643. doi: 10.1002/art.1780330505.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.1780330505</ArticleId><ArticleId IdType="pubmed">2346519</ArticleId></ArticleIdList></Reference><Reference><Citation>Petri M, et al. Derivation and validation of the systemic lupus international collaborating clinics classification criteria for systemic lupus erythematosus. Arthritis Rheum. 2012;64:2677&#x2013;2686. doi: 10.1002/art.34473.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.34473</ArticleId><ArticleId IdType="pmc">PMC3409311</ArticleId><ArticleId IdType="pubmed">22553077</ArticleId></ArticleIdList></Reference><Reference><Citation>Gladman DD, Iba&#xf1;ez D, Urowitz MB. Systemic lupus erythematosus disease activity index 2000. J. Rheumatol. 2002;29:288&#x2013;291.</Citation><ArticleIdList><ArticleId IdType="pubmed">11838846</ArticleId></ArticleIdList></Reference><Reference><Citation>Gordon C, Sutcliffe N, Skan J, Stoll T, Isenberg DA. Definition and treatment of lupus flares measured by the BILAG index. Rheumatol. Oxf. 2003;42:1372&#x2013;1379. doi: 10.1093/rheumatology/keg382.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/rheumatology/keg382</ArticleId><ArticleId IdType="pubmed">12810926</ArticleId></ArticleIdList></Reference><Reference><Citation>Gy&#xf6;ri N, et al. Disease activity patterns over time in patients with SLE: analysis of the hopkins lupus cohort. Lupus Sci. Med. 2017;4:e000192. doi: 10.1136/lupus-2016-000192.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/lupus-2016-000192</ArticleId><ArticleId IdType="pmc">PMC5307372</ArticleId><ArticleId IdType="pubmed">28243457</ArticleId></ArticleIdList></Reference><Reference><Citation>Almeida-Brasil CC, et al. Flares after hydroxychloroquine reduction or discontinuation: Results from the Systemic lupus international collaborating clinics (SLICC) inception cohort. Ann. Rheum. Dis. 2022;81:370&#x2013;378. doi: 10.1136/annrheumdis-2021-221295.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/annrheumdis-2021-221295</ArticleId><ArticleId IdType="pmc">PMC8862090</ArticleId><ArticleId IdType="pubmed">34911705</ArticleId></ArticleIdList></Reference><Reference><Citation>In&#xea;s L, et al. Identification of clinical predictors of flare in systemic lupus erythematosus patients: A 24-months prospective cohort study. Rheumatol. Oxf. 2014;53:85&#x2013;89. doi: 10.1093/rheumatology/ket322.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/rheumatology/ket322</ArticleId><ArticleId IdType="pubmed">24067885</ArticleId></ArticleIdList></Reference><Reference><Citation>Ugarte-Gil MF, et al. Predictive factors of flares in systemic lupus erythematosus patients: data from a multiethnic Latin American cohort. Lupus. 2018;27:536&#x2013;544. doi: 10.1177/0961203317728810.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/0961203317728810</ArticleId><ArticleId IdType="pubmed">28857715</ArticleId></ArticleIdList></Reference><Reference><Citation>Petri M, Singh S, Tesfasyone H, Malik A. Prevalence of flare and influence of demographic and serologic factors on flare risk in systemic lupus erythematosus: A prospective study. J. Rheumatol. 2009;36:2476&#x2013;2480. doi: 10.3899/jrheum.090019.</Citation><ArticleIdList><ArticleId IdType="doi">10.3899/jrheum.090019</ArticleId><ArticleId IdType="pubmed">19833757</ArticleId></ArticleIdList></Reference><Reference><Citation>Petri MA, et al. Baseline predictors of systemic lupus erythematosus flares: Data from the combined placebo groups in the phase III belimumab trials. Arthritis Rheum. 2013;65:2143&#x2013;2153. doi: 10.1002/art.37995.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.37995</ArticleId><ArticleId IdType="pubmed">23754628</ArticleId></ArticleIdList></Reference><Reference><Citation>Moroni G, Longhi S, Giglio E, Messa P, Ponticelli C. What happens after complete withdrawal of therapy in patients with lupus nephritis. Clin. Exp. Rheumatol. 2013;31:S75&#x2013;81.</Citation><ArticleIdList><ArticleId IdType="pubmed">24129143</ArticleId></ArticleIdList></Reference><Reference><Citation>Group CHS. A randomized study of the effect of withdrawing hydroxychloroquine sulfate in systemic lupus erythematosus. N. Engl. J. Med. 1991;324:150&#x2013;154. doi: 10.1056/nejm199101173240303.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/nejm199101173240303</ArticleId><ArticleId IdType="pubmed">1984192</ArticleId></ArticleIdList></Reference><Reference><Citation>Zeng X, et al. Risk factors for the flare of systemic lupus erythematosus and its influence on prognosis: a single-center retrospective analysis. Adv. Rheumatol. 2021;61:43. doi: 10.1186/s42358-021-00202-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s42358-021-00202-7</ArticleId><ArticleId IdType="pubmed">34215349</ArticleId></ArticleIdList></Reference><Reference><Citation>Praprotnik S, Bozic B, Kveder T, Rozman B. Fluctuation of anti-Ro/SS-A antibody levels in patients with systemic lupus erythematosus and Sj&#xf6;gren's syndrome: A prospective study. Clin. Exp. Rheumatol. 1999;17:63&#x2013;68.</Citation><ArticleIdList><ArticleId IdType="pubmed">10084034</ArticleId></ArticleIdList></Reference><Reference><Citation>Agarwal S, Harper J, Kiely PD. Concentration of antibodies to extractable nuclear antigens and disease activity in systemic lupus erythematosus. Lupus. 2009;18:407&#x2013;412. doi: 10.1177/0961203308097784.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/0961203308097784</ArticleId><ArticleId IdType="pubmed">19318392</ArticleId></ArticleIdList></Reference><Reference><Citation>Emad Y, et al. Antibodies to extractable nuclear antigens (ENAS) in systemic lupus erythematosus patients: Correlations with clinical manifestations and disease activity. Reumatismo. 2018;70:85&#x2013;91. doi: 10.4081/reumatismo.2018.1027.</Citation><ArticleIdList><ArticleId IdType="doi">10.4081/reumatismo.2018.1027</ArticleId><ArticleId IdType="pubmed">29976042</ArticleId></ArticleIdList></Reference><Reference><Citation>Ahn SS, et al. Anti-Smith antibody is associated with disease activity in patients with new-onset systemic lupus erythematosus. Rheumatol. Int. 2019;39:1937&#x2013;1944. doi: 10.1007/s00296-019-04445-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00296-019-04445-y</ArticleId><ArticleId IdType="pubmed">31552434</ArticleId></ArticleIdList></Reference><Reference><Citation>Connelly K, et al. Associations of improvement in laboratory tests with clinical outcomes in patients with active systemic lupus erythematosus: A multinational longitudinal cohort study. Lancet. Rheumatol. 2022;4:e831&#x2013;e841. doi: 10.1016/S2665-9913(22)00307-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2665-9913(22)00307-1</ArticleId></ArticleIdList></Reference><Reference><Citation>Parodis I, et al. Early B cell and plasma cell kinetics upon treatment initiation portend flares in systemic lupus erythematosus: A post-hoc analysis of three phase III Clinical trials of belimumab. Front. Immunol. 2022;13:796508. doi: 10.3389/fimmu.2022.796508.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2022.796508</ArticleId><ArticleId IdType="pmc">PMC9015703</ArticleId><ArticleId IdType="pubmed">35444642</ArticleId></ArticleIdList></Reference><Reference><Citation>Lewis MJ, Jawad AS. The effect of ethnicity and genetic ancestry on the epidemiology, clinical features and outcome of systemic lupus erythematosus. Rheumatol. Oxf. 2017;56:i67&#x2013;i77. doi: 10.1093/rheumatology/kew399.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/rheumatology/kew399</ArticleId><ArticleId IdType="pubmed">27940583</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>